Source - RNS
RNS Number : 8036K
Hikma Pharmaceuticals Plc
26 September 2016
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-executive Director/ PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

26 September 2016


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDCLBDBGLL

Related Charts

Hikma Pharmaceuticals (HIK)

+10.50p (+0.62%)
delayed 17:15PM